Defining multiple sclerosis treatment response with magnetic resonance imaging: How much activity is too much?

Archives of Neurology

Volumn 66, Issue 1, 2009, Pages 19-20

  Giacomini, Paul S ^a   Arnold, Douglas L ^b   Bar Or, Amit ^b   Antel, Jack P ^b  

^a MCGILL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE;

BRAIN ATROPHY; BRAIN TISSUE; CHRONIC DISEASE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 58449087380     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2008.529     Document Type: Editorial

References (9)

1. Chiu AW, Richert N, Ehrmantraut M, et al. Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol. 2009;66(1):39-43.
2. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol. 2004;56(4):548-555.
3. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67(6):944-953.
4. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol. 2006;60(2):236-242.
5. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346(3):158-164.
6. Sormani MP, Bruzzi P, Beckmann K, et al. The distribution of magnetic resonance imaging response to interferon beta-1b in multiple sclerosis. J Neurol. 2005;252(12):1455-1458.
7. Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63(10):1788-1795.
8. Bar-Or A. The immunology of multiple sclerosis. Semin Neurol. 2008;28(1):29-45.
9. Salomonsson S, Jonsson MV, Skarstein K, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum. 2003;48(11):3187-3201.